MedTrace Logo

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

NCT01441284 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-05-08

No results posted yet for this study

Summary

Aim of the study is to perform a double-blind, crossover, placebo-controlled multicenter study evaluating the efficacy of pramipexole on essential tremor.

Conditions

Interventions

DRUG

pramipexole

pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily

DRUG

placebo

placebo

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Principal Investigators

  • Norbert Kovacs, MD, PhD · Associate professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441284 on ClinicalTrials.gov